Company intelligence / Profile preview

Marion Laboratories

Kansas City, Missouri, United Stateskauffman.org ↗

Ownership: Private
Employees: ~3400
Development stage: Commercial

Overview

Marion Laboratories was known for marketing drugs discovered by other companies rather than conducting extensive in-house research. Their most successful product was Cardizem, a calcium channel blocker for hypertension and angina that became a blockbuster drug generating over $1 billion annually by the late 1980s[5][7].

Therapeutic areas: GastroenterologyCardiovascularNeurology
Modalities: Small molecules
Industry: Pharma

Drug pipeline

5 assets

Cardizem

Commercial

Indications: Arrhythmia, Hypertension

4 more assets in the full pipeline.

Request access →

Partnerships

Merger with Merrell Dow Pharmaceuticals (1989)[3][5][7]

Beyond the preview

Go deeper on Marion Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marion Laboratories.

Explore the full profile